"Jurassic World" and the Dinosaurs at the USDA
By Rachel Smolker,
Truthout
| 06. 22. 2015
Untitled Document
The new movie Jurassic World offers more than a few lessons relevant to the state of our world. There is the obvious point about scientists bringing back to life genetically engineered dinosaurs with no real concern for the havoc they may wreak. Then there is the very clear link to real-world "de-extinction" scientists who seriously aim to bring back mastodons and passenger pigeons, while others are finding ever more potent means to mess around with the code of life to manufacture completely new organisms through synthetic biology.
There are also the dinosaur-like regulations of the US Department of Agriculture (USDA), developed way back in the 1980s before many of the new biotechnologies were even conceived. Those regulations are in desperate need of an overhaul if they are ever to protect the public from the onslaught of dangerous and unpredictable impacts that necessarily accompany the derailing of billions of years of evolution for the purpose of corporate profit-making.
Right now in fact, the USDA is in the process of evaluating and overhauling these antiquated regulations, a process that should...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...